Alivus Life Sciences Limited (BOM: 543322)
India
· Delayed Price · Currency is INR 1,012.55
0.00 (0.00%)
At close: Dec 20, 2024
Alivus Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2018 |
| Revenue | 22,049 | 22,832 | 21,612 | 21,232 | 18,852 | 15,373 | Upgrade
|
| Revenue Growth (YoY) | -5.61% | 5.64% | 1.79% | 12.63% | 22.63% | 73.43% | Upgrade
|
| Cost of Revenue | 10,318 | 10,399 | 10,469 | 10,677 | 9,342 | 7,169 | Upgrade
|
| Gross Profit | 11,731 | 12,433 | 11,144 | 10,555 | 9,509 | 8,204 | Upgrade
|
| Selling, General & Admin | 2,745 | 2,701 | 1,896 | 1,744 | 1,553 | 1,545 | Upgrade
|
| Other Operating Expenses | 2,894 | 2,976 | 2,819 | 2,643 | 2,005 | 1,927 | Upgrade
|
| Operating Expenses | 6,211 | 6,212 | 5,136 | 4,766 | 3,892 | 3,765 | Upgrade
|
| Operating Income | 5,520 | 6,221 | 6,008 | 5,789 | 5,617 | 4,438 | Upgrade
|
| Interest Expense | -14.47 | -15.46 | -5.47 | -279.62 | -875.47 | -335.15 | Upgrade
|
| Interest & Investment Income | 120.21 | 120.21 | 157.66 | 67.81 | 4.3 | 3.55 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.37 | -6.37 | 130.23 | 76.04 | -34.59 | 112.39 | Upgrade
|
| Other Non Operating Income (Expenses) | 68.27 | 0.21 | 1.68 | 3.19 | 3.81 | 3.96 | Upgrade
|
| EBT Excluding Unusual Items | 5,688 | 6,320 | 6,292 | 5,657 | 4,715 | 4,223 | Upgrade
|
| Gain (Loss) on Sale of Assets | -7.04 | -7.04 | -5.58 | -7.43 | -5.84 | -12.3 | Upgrade
|
| Pretax Income | 5,681 | 6,313 | 6,286 | 5,649 | 4,709 | 4,211 | Upgrade
|
| Income Tax Expense | 1,446 | 1,604 | 1,616 | 1,462 | 1,194 | 1,080 | Upgrade
|
| Net Income | 4,235 | 4,709 | 4,670 | 4,187 | 3,516 | 3,131 | Upgrade
|
| Net Income to Common | 4,235 | 4,709 | 4,670 | 4,187 | 3,516 | 3,131 | Upgrade
|
| Net Income Growth | -16.23% | 0.84% | 11.52% | 19.10% | 12.29% | 60.08% | Upgrade
|
| Shares Outstanding (Basic) | 123 | 123 | 123 | 118 | 108 | 108 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 123 | 123 | 118 | 108 | 108 | Upgrade
|
| Shares Change (YoY) | 0.28% | 0.13% | 4.25% | 9.02% | - | 35.79% | Upgrade
|
| EPS (Basic) | 34.56 | 38.43 | 38.11 | 35.63 | 32.61 | 29.04 | Upgrade
|
| EPS (Diluted) | 34.46 | 38.38 | 38.11 | 35.63 | 32.61 | 29.04 | Upgrade
|
| EPS Growth | -16.47% | 0.71% | 6.97% | 9.26% | 12.29% | 17.88% | Upgrade
|
| Free Cash Flow | 2,650 | 2,845 | 1,432 | 4,654 | 3,201 | 1,438 | Upgrade
|
| Free Cash Flow Per Share | 21.57 | 23.19 | 11.69 | 39.60 | 29.69 | 13.34 | Upgrade
|
| Dividend Per Share | - | 22.500 | 21.000 | 21.000 | - | - | Upgrade
|
| Dividend Growth | - | 7.14% | 0% | - | - | - | Upgrade
|
| Gross Margin | 53.21% | 54.45% | 51.56% | 49.71% | 50.44% | 53.36% | Upgrade
|
| Operating Margin | 25.03% | 27.25% | 27.80% | 27.27% | 29.80% | 28.87% | Upgrade
|
| Profit Margin | 19.21% | 20.62% | 21.61% | 19.72% | 18.65% | 20.37% | Upgrade
|
| Free Cash Flow Margin | 12.02% | 12.46% | 6.63% | 21.92% | 16.98% | 9.36% | Upgrade
|
| EBITDA | 6,027 | 6,691 | 6,394 | 6,141 | 5,940 | 4,723 | Upgrade
|
| EBITDA Margin | 27.34% | 29.31% | 29.58% | 28.92% | 31.51% | 30.72% | Upgrade
|
| D&A For EBITDA | 507.23 | 469.84 | 386.04 | 351.91 | 322.9 | 284.85 | Upgrade
|
| EBIT | 5,520 | 6,221 | 6,008 | 5,789 | 5,617 | 4,438 | Upgrade
|
| EBIT Margin | 25.03% | 27.25% | 27.80% | 27.27% | 29.80% | 28.87% | Upgrade
|
| Effective Tax Rate | 25.45% | 25.41% | 25.72% | 25.88% | 25.35% | 25.64% | Upgrade
|
| Revenue as Reported | 22,237 | 22,953 | 21,902 | 21,379 | 18,860 | 15,493 | Upgrade
|
| Advertising Expenses | - | 115.47 | 90.07 | 54.96 | 60.55 | 121.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.